Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1369700 | 0.98 | L3MBTL1 (0.65) | L3MBTL1NUDT1HTR2CHTR2AAXL | |
| SCHEMBL2914112 | 0.82 | L3MBTL1 (0.65) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL3847774 | 0.80 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL15007643 | 0.80 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL1983144 | 0.80 | L3MBTL1 (0.49) | L3MBTL1NUDT1HTR2CAXLTNKS | |
| SCHEMBL1348114 | 0.80 | L3MBTL1 (1.00) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL1348141 | 0.80 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL12144260 | 0.80 | L3MBTL1 (0.62) | L3MBTL1NUDT1HTR2CHTR2ATNKS | |
| SCHEMBL15747098 | 0.80 | L3MBTL1 (0.49) | L3MBTL1NUDT1HTR2CAXLTNKS | |
| SCHEMBL2266179 | 0.80 | L3MBTL1 (0.58) | L3MBTL1NUDT1HTR2CAXLTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307413-B1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | HOFFMANN LA ROCHE (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2300466-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8742098-B2 | Inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742098-B2 | Inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2307413-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| WO-2010006947-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| WO-2009155388-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155389-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | L3MBTL1 3259/4885NUDT1 3091/4885HTR2C 4531/4885 |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | L3MBTL1 2631/4885NUDT1 3544/4885HTR2C 2556/4885 |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K8 | L3MBTL1 4234/4885NUDT1 1305/4885HTR2C 988/4885 |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP3K5 | L3MBTL1 4224/4885NUDT1 1499/4885HTR2C 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.